Qingxiang (Nick) Lin, PhD, is The Journal of Pharmacology and Experimental Therapeutics Highlighted Trainee Author for June 2021. He received his PhD in biophysical oncology at Roswell Park Comprehensive Cancer Center and University at Buffalo, SUNY. He has been under the mentorship of Dr. Robert M. Straubinger, distinguished professor of pharmaceutical sciences, SUNY, for his PhD and postdoctoral research. Next, he will go to Harvard University for his postdoctoral training in cancer pharmacology. The JPET article that earned his selection as a Highlighted Trainee Author is titled "Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation" and is available at https://doi.org/10.1124/jpet.120.000412.
Dr. Lin's area of research is in cancer pharmacology and therapeutics using multi-disciplinary approaches. His PhD research has demonstrated the molecular mechanisms and roles of fibroblast growth factor receptors (FGFR) in pancreatic cancer progression and chemo-resistance. In this publication, Dr. Lin has used both mathematical and experimental approaches to quantitatively prove that FGFR inhibition enhances the effects of gemcitabine, the standard of care for pancreatic cancer. He did this by sensitizing pancreatic cancer cells and tumors to gemcitabine-mediated inhibition of proliferation and cell cycle arrest. This is a clinically deployable approach of potential benefit to pancreatic cancer patients.
The anticipated impact of Dr. Lin's research is to elucidate the molecular mechanisms of chemo-resistance in pancreatic cancer and translate the drug combination regimens to clinic use.
When not in the lab, Qingxiang enjoys music, talk shows, sports, and art.